Freestone Grove Partners LP Makes New $124.57 Million Investment in Abbott Laboratories $ABT

Key Points

• Freestone Grove Partners LP initiated a $124.57 million position in Abbott Laboratories, buying 1.37 million shares during the second quarter. Abbott now represents about 0.8% of the firm’s portfolio, while institutional investors collectively own 75.18% of the stock.
• Abbott reported quarterly adjusted earnings of $1.31 per share and revenue of $12.59 billion, beating analyst estimates; revenue grew 13% year over year. Management guided for full-year 2026 EPS of $5.45 to $5.60.
• The stock recently traded at $110.52 and pays a quarterly dividend of $0.63, equivalent to a 2.3% yield. Analysts maintain a broadly positive outlook, with a consensus “Moderate Buy” rating and an average price target of $119.50.

Freestone Grove Partners LP purchased a new stake in Abbott Laboratories (NYSE:ABT - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,372,846 shares of the healthcare product maker's stock, valued at approximately $124,572,000. Abbott Laboratories accounts for about 0.8% of Freestone Grove Partners LP's investment portfolio, making the stock its 11th biggest holding. Freestone Grove Partners LP owned approximately 0.08% of Abbott Laboratories as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. raised its holdings in Abbott Laboratories by 4.6% in the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock worth $13,843,610,000 after acquiring an additional 6,769,518 shares during the period. State Street Corp boosted its holdings in Abbott Laboratories by 2.1% during the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker's stock valued at $10,004,880,000 after acquiring an additional 1,627,791 shares during the period. Capital International Investors boosted its holdings in Abbott Laboratories by 2.6% during the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker's stock valued at $7,922,519,000 after acquiring an additional 1,614,706 shares during the period. J. Stern & Co. LLP grew its position in shares of Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the last quarter. Finally, Capital Research Global Investors increased its stake in shares of Abbott Laboratories by 1.0% in the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker's stock worth $4,907,523,000 after purchasing an additional 400,400 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Trading Up 1.5%

Shares of ABT opened at $110.52 on Thursday. The stock's 50-day moving average price is $103.83 and its 200 day moving average price is $100.09. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The firm has a market capitalization of $191.24 billion, a price-to-earnings ratio of 35.77, a P/E/G ratio of 2.02 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories's payout ratio is 81.55%.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott outperformed the market during the latest trading session, supported by continued investor interest in the diversified healthcare-products maker. Its shares are trading above both the 50-day and 200-day moving averages, indicating favorable near-term momentum. Abbott Exceeds Market Returns: Some Facts to Consider
• Positive Sentiment: Abbott’s latest reported quarter showed solid fundamentals: adjusted earnings exceeded consensus estimates, revenue surpassed expectations, and sales increased 13% year over year. Management’s 2026 earnings guidance remains consistent with analyst expectations, helping support the investment case.
• Neutral Sentiment: Industry research projects continued growth in cardiovascular ultrasound systems through 2030, driven by portable devices, artificial intelligence, 3D/Doppler imaging and remote diagnostics. The opportunity is broadly relevant to Abbott’s cardiovascular-device business, although the report primarily highlights GE HealthCare, Philips and Siemens Healthineers rather than announcing a specific Abbott development. Cardiovascular Ultrasound Systems Market Outlook
• Neutral Sentiment: Recent commentary notes that Abbott has lagged the healthcare sector over the past year, but analysts remain broadly optimistic about its long-term prospects. This creates a mixed backdrop: valuation and relative performance could restrain gains, while analyst confidence and business diversification provide support. Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector?

Analyst Ratings Changes

Several equities analysts recently weighed in on ABT shares. JPMorgan Chase & Co. boosted their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the stock an "overweight" rating in a research report on Friday, July 17th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. TD Cowen upped their price target on Abbott Laboratories from $115.00 to $135.00 and gave the stock a "buy" rating in a report on Tuesday, August 25th. Robert W. Baird initiated coverage on Abbott Laboratories in a research report on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 price objective for the company. Finally, Bank of America lowered their price objective on shares of Abbott Laboratories from $120.00 to $102.00 in a research note on Friday, June 12th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $119.50.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source